Latest news with #Farr
USA Today
15 hours ago
- Sport
- USA Today
Promising Texas A&M infielder confirms return to College Station for sophomore season
Texas A&M baseball head coach Michael Earley retained another promising infielder for next year's club, as the No. 3 shortstop in Texas from the 2024 class is reportedly returning for his sophomore season in College Station. According to TexAgs analyst Ryan Brauninger, Fort Worth native Sawyer Farr confirmed he will gear up for the Aggies in 2026. He made 31 starts in 39 appearances with 15 hits, including a triple, 17 walks and four RBI. The announcement from Farr will provide Earley with another up-and-comer who has the potential to become a superstar for the Aggies baseball program. Perfect Game USA ranked the 6-foot-4-inch shortstop as the No. 17 prospect at his position and the No. 67 overall player in the country from his class. Although the opportunity was there for Farr to go pro and potentially sign with a Major League Baseball franchise, he signed with the Aggies. Heading into the 2025 campaign, the freshman joined fellow teammate and outfielder Terrence Kiel II as the two Aggies to make Perfect Game USA's Top 75 Freshman list. According to the outlet's evaluation of Farr during Texas A&M's fall ball in 2024, he showed promise from both sides of the plate entering his first season in Aggieland. "Armed with real switch hit juice, true freshman Sawyer Farr, hit some balls extremely hard in looks and got some good starts at second base, though the frame and athlete may move him to the left side of the dirt long term." Both Farr and Kiel are now officially returning for their sophomore seasons in the Maroon and White uniform, which provides Earley's club with speed on the basepath and consistent hitting at the plate if they reach their full potential. Farr's announcement on Saturday night continues to grow the flame that the Aggies are trying to build back as preparations begin for offseason work in College Station. Contact/Follow us @AggiesWire on X (formerly Twitter) and like our page on Facebook to follow ongoing coverage of Texas A&M news, notes and opinions. Follow Dylan on X: @dylanmflippo.
CNBC
11-06-2025
- Business
- CNBC
How to capitalize on the red-hot quantum computing space, according to a veteran investor
For investors looking to capitalize on the popular quantum computing space, it's better to cast a wide net, according to Michael Farr, CEO of Farr, Miller and Washington. Farr broke down his views on the red-hot quantum computing stocks, Dave & Buster's and Amazon on CNBC's "Three-Stock Lunch" Wednesday. Quantum ETF The longtime investor said it's difficult to identify true winners in the crowded space, so investors should consider exchange traded funds like the Defiance Quantum & AI ETF . Quantum computing stocks skyrocketed Wednesday after Nvidia CEO Jensen Huang said at a developers conference that the space was reaching an inflection point . Shares of Quantum Computing surged 24%, while Rigetti Computing soared about 17%. "I would own the ETF, because you can't know which one of these is going to be successful. It's early stages. You own a whole bunch of them, with some established companies in there too," Farr said. "I would not make an individual bet. I'd make a broader cast." Quantum computers are machines that use the laws of quantum mechanics to solve problems too complex for traditional computers, which store information in bits. Dave & Buster's Dave & Buster's shares jumped double digits Wednesday after the company's comparable sales fell less than expected. However, Farr said he would not own the restaurant and entertainment company because of its weak fundamentals. "As a long-term fundamental investor, they don't have a lot of cash. They do have a lot of debt. As a company, you don't have flexibility. If today you own it, you feel good. Tomorrow will be a great day not to own it," Farr said. "I would get out and put my money somewhere more predictable." Amazon The investor revealed that he is a fan of Amazon as the tech giant made a $20 billion investment on two data center complexes in Pennsylvania. "I think that over the next five years, you're going to be very happy owning this one," Farr said. "They have a lot of cash. They've got a great deal of opportunity." One of the complexes Amazon is building will be alongside a nuclear power plant . According to an Associated Press report, the plan has drawn scrutiny over an arrangement to essentially plug right into the power plant.
CNBC
11-06-2025
- Business
- CNBC
Three Stock Lunch: Dave & Buster's, Amazon and the Quantum space
Michael Farr, Farr, Miller and Washington CEO, joins 'Power Lunch' to discuss Farr's investing take on three stocks: Dave & Buster's, Amazon and the Quantum space.
South Wales Guardian
06-06-2025
- Health
- South Wales Guardian
Vaginal mesh particles ‘could trigger autoimmune response even after removal'
Experts suggest allergy testing patients before they are fitted with mesh may help to better understand why complications happen in some cases. Campaign group Sling the Mesh said the majority of its members have developed a reaction they believe is down to the material, including autoimmune diseases, unexplained rashes and chronic fatigue. Transvaginal mesh (TVM) implants are made from synthetic materials such as polypropylene, a type of thermoplastic, and have been used to treat pelvic organ prolapse and incontinence after childbirth. However, they can cause serious harm to some women, with side effects including infection, pelvic pain, and incontinence. The NHS restricted its use of TVM implants in 2018 and they are now used only as a last resort through a high-vigilance programme of restricted practice. A new article led by Dr Nicholas Farr, published in the journal Nature Reviews Urology, analysed studies which suggest polypropylene is a material which causes autoimmune/inflammatory syndrome induced by adjuvants (Asia). Asia arises following exposure to substances that enhance the immune response in the likes of vaccines, silicone implants, or other foreign materials. Symptoms can vary widely, but include chronic fatigue and chronic pain. It comes after previous work by Dr Farr, who is a research fellow at the University of Sheffield, showed polypropylene mesh started to degrade within 60 days of being implanted in the pelvis of sheep. The study also found particles of polypropylene in the tissue surrounding implant sites. Dr Farr told the PA news agency: 'Our previous studies have shown that polypropylene mesh can degrade and leave behind particles within the surrounding tissues. 'This is important because it raises a key question – what kind of clinical response might these particles trigger?' 'Earlier studies have explored links between mesh implants and systemic symptoms resembling Asia. Patients often reported that symptoms improved after mesh removal, but in some cases, they didn't fully resolve. 'These cases were described as involving 'complete' mesh removal. But our findings challenge that definition. 'We've shown that even after the mesh has been surgically removed, polypropylene particles can persist in the tissue. 'So, it may not be a truly complete removal – and that could help explain why symptoms persist in a subset of patients. 'Our findings offer a new perspective on earlier studies, suggesting that residual particles might be a contributing factor in ongoing immune responses, even after the visible mesh is gone.' Dr Farr called for 'increased clinical surveillance of mesh patients' to keep track of any autoimmune symptoms, as well as allergy tests to consider suitability before they are implanted. He added: 'While it is important to recognise that the majority of mesh implants do not result in serious complications, we need to better understand why complications arise in a subset of patients and ensure those experiences are not overlooked. 'It is also essential that we engage with patients who have lived experience of mesh complications, as their insights are vital to improving future care and guiding the responsible development of safer medical devices.' Reacting to Dr Farr's latest findings, Kath Sansom, founder of campaign group Sling The Mesh, told PA it 'confirms what thousands of mesh injured patients have been reporting for years – that polypropylene mesh can lead to autoimmune disease, fibromyalgia and allergic reactions'. 'For too long, our voices have been dismissed,' she added. 'Now, science is catching up, and it's imperative that regulators and manufacturers take immediate action to prevent further harm.' Ms Sansom told PA the findings underscore the need for revaluation of the material used in mesh, along with the importance of 'patient-centred approaches'. 'The majority of our group – nearly 12,000 people – have developed some sort of reaction believed to be from the plastic mesh including a wide range of autoimmune diseases, unexplained rashes, IBS, dry eyes and chronic fatigue,' she added. Sharron Mahoney, 57, claims the vaginal mesh she had implanted in 2010 caused her immune system to go 'into overdrive', with symptoms either easing or disappearing when she had it removed in 2018. She said: 'After receiving a rectopexy mesh implant, I began suffering from a host of unexplained symptoms – severe fatigue, joint pain, recurring rashes, and food and chemical sensitivities that I had never experienced before. 'I couldn't grip anything, was losing my vision, had chronic cough, post nasal drip. Dry eyes. Stiff and sore muscles. Rashes on my skin. 'Doctors struggled to find a cause and treated me like a mystery – I later found out they put 'may be psychological' in my notes. 'When I finally had the mesh removed, the change was extraordinary – the allergic reactions instantly eased, my energy slowly returned, and many of the autoimmune symptoms diminished or disappeared entirely. 'My experience has left me in no doubt that the mesh was causing my immune system to go into overdrive. 'Patients need to be heard, and we need robust, long-term research and regulation to prevent others from suffering needlessly.' A 2024 report by Patient Safety Commissioner Dr Henrietta Hughes highlighted that thousands of women's lives were 'destroyed' because of pelvic mesh. It called for the Government to create a two-stage financial redress scheme. However, in February – a year on from the report's publication – campaigners said they have 'faced silence', with no compensation scheme put in place.
The Herald Scotland
06-06-2025
- Health
- The Herald Scotland
Vaginal mesh particles ‘could trigger autoimmune response even after removal'
Campaign group Sling the Mesh said the majority of its members have developed a reaction they believe is down to the material, including autoimmune diseases, unexplained rashes and chronic fatigue. Transvaginal mesh (TVM) implants are made from synthetic materials such as polypropylene, a type of thermoplastic, and have been used to treat pelvic organ prolapse and incontinence after childbirth. However, they can cause serious harm to some women, with side effects including infection, pelvic pain, and incontinence. The NHS restricted its use of TVM implants in 2018 and they are now used only as a last resort through a high-vigilance programme of restricted practice. A new article led by Dr Nicholas Farr, published in the journal Nature Reviews Urology, analysed studies which suggest polypropylene is a material which causes autoimmune/inflammatory syndrome induced by adjuvants (Asia). Asia arises following exposure to substances that enhance the immune response in the likes of vaccines, silicone implants, or other foreign materials. Symptoms can vary widely, but include chronic fatigue and chronic pain. It comes after previous work by Dr Farr, who is a research fellow at the University of Sheffield, showed polypropylene mesh started to degrade within 60 days of being implanted in the pelvis of sheep. The study also found particles of polypropylene in the tissue surrounding implant sites. Dr Farr told the PA news agency: 'Our previous studies have shown that polypropylene mesh can degrade and leave behind particles within the surrounding tissues. 'This is important because it raises a key question – what kind of clinical response might these particles trigger?' 'Earlier studies have explored links between mesh implants and systemic symptoms resembling Asia. Patients often reported that symptoms improved after mesh removal, but in some cases, they didn't fully resolve. 'These cases were described as involving 'complete' mesh removal. But our findings challenge that definition. 'We've shown that even after the mesh has been surgically removed, polypropylene particles can persist in the tissue. 'So, it may not be a truly complete removal – and that could help explain why symptoms persist in a subset of patients. 'Our findings offer a new perspective on earlier studies, suggesting that residual particles might be a contributing factor in ongoing immune responses, even after the visible mesh is gone.' Dr Farr called for 'increased clinical surveillance of mesh patients' to keep track of any autoimmune symptoms, as well as allergy tests to consider suitability before they are implanted. He added: 'While it is important to recognise that the majority of mesh implants do not result in serious complications, we need to better understand why complications arise in a subset of patients and ensure those experiences are not overlooked. 'It is also essential that we engage with patients who have lived experience of mesh complications, as their insights are vital to improving future care and guiding the responsible development of safer medical devices.' Reacting to Dr Farr's latest findings, Kath Sansom, founder of campaign group Sling The Mesh, told PA it 'confirms what thousands of mesh injured patients have been reporting for years – that polypropylene mesh can lead to autoimmune disease, fibromyalgia and allergic reactions'. 'For too long, our voices have been dismissed,' she added. 'Now, science is catching up, and it's imperative that regulators and manufacturers take immediate action to prevent further harm.' Ms Sansom told PA the findings underscore the need for revaluation of the material used in mesh, along with the importance of 'patient-centred approaches'. 'The majority of our group – nearly 12,000 people – have developed some sort of reaction believed to be from the plastic mesh including a wide range of autoimmune diseases, unexplained rashes, IBS, dry eyes and chronic fatigue,' she added. Sharron Mahoney, 57, claims the vaginal mesh she had implanted in 2010 caused her immune system to go 'into overdrive', with symptoms either easing or disappearing when she had it removed in 2018. She said: 'After receiving a rectopexy mesh implant, I began suffering from a host of unexplained symptoms – severe fatigue, joint pain, recurring rashes, and food and chemical sensitivities that I had never experienced before. 'I couldn't grip anything, was losing my vision, had chronic cough, post nasal drip. Dry eyes. Stiff and sore muscles. Rashes on my skin. 'Doctors struggled to find a cause and treated me like a mystery – I later found out they put 'may be psychological' in my notes. 'When I finally had the mesh removed, the change was extraordinary – the allergic reactions instantly eased, my energy slowly returned, and many of the autoimmune symptoms diminished or disappeared entirely. 'My experience has left me in no doubt that the mesh was causing my immune system to go into overdrive. 'Patients need to be heard, and we need robust, long-term research and regulation to prevent others from suffering needlessly.' A 2024 report by Patient Safety Commissioner Dr Henrietta Hughes highlighted that thousands of women's lives were 'destroyed' because of pelvic mesh. It called for the Government to create a two-stage financial redress scheme. However, in February – a year on from the report's publication – campaigners said they have 'faced silence', with no compensation scheme put in place.
